Related Experiment Videos
Diabetic ketoacidosis during NovoPen therapy
1Diabetic Unit, Glasgow Royal Infirmary, Scotland.
Summary
NovoPen therapy for diabetes management led to diabetic ketoacidosis in young patients. Careful monitoring is crucial, as this insulin regimen may increase risks for those not diligently controlling their condition.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Pharmacology
Background:
- Exploring alternative insulin delivery methods to enhance flexibility and patient adherence in diabetes management.
- Investigating the suitability of NovoPen therapy for young individuals (15-26 years) with diabetes.
Observation:
- Five young patients transitioned to a NovoPen regimen involving Human Actrapid and Human Ultratard insulin.
- Development of diabetic ketoacidosis occurred within 2-4 months in all patients, with one experiencing it twice in 4 weeks.
Findings:
- Patients struggled to adjust insulin doses for hyperglycemia, with some omitting insulin during missed meals.
- This regimen was associated with an increased risk of diabetic ketoacidosis, particularly in patients with suboptimal diabetes control.
Implications:
- NovoPen therapy requires assiduous patient monitoring and education to mitigate the risk of diabetic ketoacidosis.
- This insulin delivery system may not be appropriate for poorly motivated or inadequately educated patients managing diabetes.